Sulforaphane for Cancer Risk Reduction

Research suggests that sulforaphane and related compounds capable of activating the Nrf2 pathway may have some relevance to cancer risk reduction through their effects on cellular antioxidant defenses and inflammation, though the studies provided here do not directly investigate sulforaphane or cancer outcomes. The available evidence consists entirely of laboratory-based cell culture experiments focused on SARS-CoV-2 infection, examining how Nrf2 activation, mucociliary function, and herbal compounds affect viral replication and inflammatory gene expression. While Nrf2 activation — a mechanism associated with sulforaphane — did show effects on inflammatory cytokines and viral entry genes in cell models, none of these findings speak to cancer risk reduction in humans, and no clinical trials, observational studies, or meta-analyses on that question are represented in this evidence base. Readers interested in sulforaphane's relationship to cancer risk should be aware that the studies provided here do not support conclusions in that area, and the broader scientific literature on that specific question would need to be consulted separately.